Back
Results - Announcements
Natco Pharma Ltd consolidated sales down 0.53% on year in Q2FY2026
14-Aug-2026, 05:35
Natco Pharma Ltd share price inched up 4.07% to Rs 952.25. The Company's net profit tanked by 47.62% to Rs 122.2 crore, while revenue from operations eased by 0.53% to Rs 735.2 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.19 lakh crore, gaining 4.69%. It has marginally improved by 0.66% over last one week and moving up by 11.20% in last one month while the market capitalization of Natco Pharma Ltd has improved by 3.83% and 20.49% in the same period respectively. Profit before tax (PBT) of Natco Pharma Ltd stood at Rs 185.6 crore in Q2 FY26, tumbling by 67.55% year-on-year, and surging by 28.80% quarter-on-quarter. EBITDA came in at Rs 127 crore, nosediving by 75.00% YoY and expanding by 155.62% sequentially. Total expenses slightly declined by 9.99% to Rs 595.8 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 157.8 crore, soaring by 53.50% YoY, while employee benefits expense was at Rs 179.3 crore, witnessing a strong rise of 13.12% YoY. For the TTM ended FY26, revenue from operations rose 10.77% to Rs 4429.5 crore, while net profit jumped 35.66% to Rs 1883.4 crore, compared to previous TTM. EBITDA jumped by 167070% to Rs 1841.5 crore, and PBT surged 36.92% to Rs 2291.4 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 1696.8 crore in FY26, as against Rs 1211.6 crore in FY25. Natco Pharma Ltd climbed 5.32% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 3.05% during the same period.
Natco Pharma Ltd share price inched up 4.07% to Rs 952.25. The Company's net profit tanked by 47.62% to Rs 122.2 crore, while revenue from operations eased by 0.53% to Rs 735.2 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.19 lakh crore, gaining 4.69%. It has marginally improved by 0.66% over last one week and moving up by 11.20% in last one month while the market capitalization of Natco Pharma Ltd has improved by 3.83% and 20.49% in the same period respectively. Profit before tax (PBT) of Natco Pharma Ltd stood at Rs 185.6 crore in Q2 FY26, tumbling by 67.55% year-on-year, and surging by 28.80% quarter-on-quarter. EBITDA came in at Rs 127 crore, nosediving by 75.00% YoY and expanding by 155.62% sequentially. Total expenses slightly declined by 9.99% to Rs 595.8 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 157.8 crore, soaring by 53.50% YoY, while employee benefits expense was at Rs 179.3 crore, witnessing a strong rise of 13.12% YoY. For the TTM ended FY26, revenue from operations rose 10.77% to Rs 4429.5 crore, while net profit jumped 35.66% to Rs 1883.4 crore, compared to previous TTM. EBITDA jumped by 167070% to Rs 1841.5 crore, and PBT surged 36.92% to Rs 2291.4 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 1696.8 crore in FY26, as against Rs 1211.6 crore in FY25. Natco Pharma Ltd climbed 5.32% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 3.05% during the same period.